TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) just unveiled an announcement.
Recce Pharmaceuticals Ltd announced a change in the director’s interest, specifically concerning James Graham, who has disposed of 745,962 Class B Performance Shares through a selective buy-back approved by shareholders. This change reflects a strategic adjustment in the company’s equity structure, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd is a company operating in the pharmaceutical industry, focusing on the development of new classes of synthetic anti-infectives. The company aims to address the growing issue of antibiotic resistance by providing innovative solutions for treating serious infections.
Average Trading Volume: 133,385
Technical Sentiment Signal: Hold
Current Market Cap: A$117.1M
See more data about RCE stock on TipRanks’ Stock Analysis page.